Published in final edited form as:

Eur J Pharm Biopharm. 2019 November 01; 144: 11–17. doi:10.1016/j.ejpb.2019.09.006.

Advanced *in vitro* lung-on-chip platforms for inhalation assays: from prospect to pipeline

Arbel Artzy-Schnirman¹, Nina Hobi^{2,3}, Nicole Schneider-Daum^{4,5}, Olivier T. Guenat^{2,3,6,7}, Claus-Michael Lehr^{4,5}, Josué Sznitman^{1,*}

¹Department of Biomedical Engineering, Technion – Israel Institute of Technology, Haifa 32000, Israel

²ARTORG Center for Biomedical Engineering Research, University of Bern, Switzerland

³AlveoliX AG, Bern, Switzerland

⁴Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University, 66123 Saarbrücken, Germany

⁵Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany

⁶Department of Pulmonary Medicine, University of Bern, Switzerland

⁷Division of Thoracic Surgery, University of Bern, Switzerland

Abstract

With rapid advances in micro-fabrication processes and the availability of biologically-relevant lung cells, the development of *lung-on-chip* platforms is offering novel avenues for more realistic inhalation assays in pharmaceutical research, and thereby an opportunity to depart from traditional *in vitro* lung assays. As advanced models capturing the cellular pulmonary make-up at an air-liquid interface (ALI), *lung-on-chips* emulate both morphological features and biological functionality of the airway barrier with the ability to integrate respiratory breathing motions and ensuing tissue strains. Such *in vitro* systems allow importantly to mimic more realistic physiological respiratory flow conditions, with the opportunity to integrate physically-relevant transport determinants of aerosol inhalation therapy, i.e. recapitulating the pathway from airborne flight to deposition on the airway lumen. In this short opinion, we discuss such points and describe how these attributes are paving new avenues for exploring improved drug carrier designs (e.g. shape, size, etc.) and targeting strategies (e.g. conductive vs. respiratory regions) amongst other. We argue that while technical challenges still lie along the way in rendering *in vitro lung-on-chip* platforms more widespread across the general pharmaceutical research community, significant momentum is steadily underway in accelerating the prospect of establishing these as *in vitro* “gold standards”.

*Corresponding author: sznitman@bm.technion.ac.il.

Conflict of Interest

CM Lehr is co-founder, scientific advisor and shareholder of PharmBioTec GmbH, Saarbrücken, Germany. OT Guenat and N Hobi are shareholders of the start-up AlveoliX AG.

Keywords

organ-on-chip ; microfluidics; inhalation assays; aerosols; cellular airway barrier

Introduction

Respiratory diseases are a global leading cause of disability and mortality, with lifestyle and environmental factors contributing to their growing prevalence and association with rising healthcare and economic burden [1]. Chronic Obstructive Pulmonary Disease (COPD) alone, with 200 million patients suffering from moderate to severe forms of it [2] is the third leading cause of death worldwide. In parallel, lung cancer (i.e. the most common worldwide), acute respiratory distress syndrome (ARDS) [3], idiopathic pulmonary fibrosis (IPF) as well as infectious diseases (e.g. pneumonia, tuberculosis) are all either fatal diseases or pathologies exhibiting high mortality rates. Despite an unmet need in treating respiratory diseases, few new compounds that are safe show efficacy and have eventually emerged as new therapeutic options. The success rate for the approval of novel inhalation medicine in the past forty years or so has been meager at best, whereby treatments approved have mainly consisted in improvements on existing classes of drug (e.g. long-acting β_2 -agonists, long-acting muscarinic antagonists, safer inhaled corticosteroids and longer acting antibiotics). A widely acknowledged issue lies in the discrepancy between the performance of therapeutic candidate molecules in preclinical animal models and their disproportionately high failure rate for safety and/or efficacy issues upon reaching the stage of clinical trials [1].

To address the disconnect between the predictive capacity of *in vivo* animal models and delivering novel therapeutics for inhalation therapy, several alternative *in vitro* technologies capable of mimicking more accurately respiratory human physiology *in vivo* have been explored. In recent years, *organ-on-chips* (OOC) have been emerging as potential alternatives to animal testing [4]. OOCs are platforms that provide cells with an *in vitro* environment that attempts to more closely resemble their native *in vivo* milieu. In such conditions, cells can maintain a notionally naïve phenotype or can be cued to differentiate into a phenotype in a controlled manner [5–7]. Although OOC models have already shown promising success in reproducing complex biological functions [8–11], such as in recapitulating lung edema formation or thrombosis [8], these systems and their wider use still remain in their infancy; their potential is only slowly starting to become more suitable for meaningful exploitation. In particular, the lungs comprise a highly-intricate organ exhibiting a multiscale challenge to replicate more realistically *in vitro* with so-called *lung-on-chip* platforms. This is especially critical when considering the transport and delivery of inhalation medicine, i.e. from mouth to airway deposition (Fig. 1), in conjunction with their effects on lung tissue including importantly translocation processes across the air-blood barrier. In this short opinion paper, we discuss in brief the current state of *lung-on-chips*, and more specifically leveraging such technologies as attractive tools for *in vitro* inhalation assays across the wider pharmaceutical research community.

From Traditional *In Vitro* Models to *Lung-on-Chip* Platforms

In vitro exposure assays for safety and efficacy assessment of given therapeutic drugs are still commonly conducted via instillations of a liquid suspension directly onto a cellular lung model. Broadly speaking, such approaches constitute the state-of-the-art whether simple epithelial monolayers (e.g. bronchial or alveolar) or rather co-/multi cell cultures (i.e. AECs, macrophages, dendritic cells, endothelium, etc.) are modeled. In mimicking more realistically the innate pulmonary environment, the adoption of transwell inserts has been increasingly popular in an effort to develop lung *in vitro* models, as “hardware” platforms, that enable lung cells to be cultured at an air-liquid interface (ALI). In past years, this has been visible within academic research communities as extensively discussed in a number of recent reviews [12,13] and is becoming more widely available commercially with companies providing ALI-based products to both the R&D sector and academic laboratories. Yet, historically, the use of instillation assays under submerged conditions, i.e. with cells grown at a liquid-liquid interface (LLI), has long acted as a “gold standard”, i.e. considered as cell systems that mimic *in vitro* key events known to occur *in vivo*. One of the significant drawbacks of such *in vitro* pulmonary LLI assays lies in the ongoing lack of realism in replicating *in situ* inhaled delivery protocols. Delivering for example aerosolized toxic compounds (e.g. zinc oxide nanoparticles) at an ALI has been shown to elevate levels of secreted pro-inflammatory markers compared with submerged cell cultures [14]; a point that has drawn attention in further advocating the need for ALI-based cytotoxicity assays [7]. For therapeutic research, such considerations apply most notably to the aerosolization of liquid droplets via a nebulizer or metered dose inhaler (MDI), or alternatively the administration of particulate matter (PM) via dry powder inhalers (DPI). The evaluation of realistic aerosol deposition outcomes in relation for example to efficacy or toxicity of a clinical inhalation therapy is still limited; a point we will return to further below.

Undeniably microfluidic systems, and more generally microfabrication technologies, have catalyzed important progress in devising advanced platforms that break away from traditional *in vitro* “hardware” [4,15]. This is especially true in the field of lung research as epitomized with the first *lung-on-chip* published nearly a decade ago [16,17], and the rapid development of some of the most advanced pre-clinical *in vitro* human models of lung pathologies [18], with therapeutic end points geared for example at pharmacokinetics and - dynamics. In particular, the field has seen a surge in the availability various microfluidic architecture designs. Though micro-devices typically feature three-dimensional (3D) geometries that enable (air-) flow through channels, lung cells (be it mono- or co-cultures) are typically grown at an ALI on a two-dimensional (2D) substrate, often times employing the same porous polyethylene terephthalate (PET) membranes used in commercially-available transwell inserts. While progress is now underway in devising *in vitro* platforms featuring cell cultures across the entire lumen (e.g. with hydrogels [19]), existing *lung-on-chips* that employ for instance polydimethylsiloxane (PDMS) or biological membranes [20] are enabling for the first time new biological read-outs (e.g. creation of a lung edema following the disruption of the lung alveolar barrier via cytokines IL-2 or the stiffening of a membrane while cells form a confluent layer [21]). Such quantifications are brought in addition to the palette of biological endpoints available in more traditional assays,

i.e. cell viability, gene expression, inflammatory cytokine responses and epithelial barrier properties amongst other. Furthermore, and of critical importance, unlike transwell and other traditional setups that are largely static when considering the exchange and/or collection (e.g. analytics of inflammation, etc.) of media, microfluidic platforms offer the integration of continuous perfusion from either the basal and/or apical side, depending on the application and the measurement end-points.

The realm of *lung-on-chips* provides tangible new opportunities to integrate critical anatomical, physiological and biological parameters *in vitro*, thereby contributing to more realistic models of (human) lung physiology [11]. Broadly speaking, their novelty may be categorized as spanning four novel characteristics that have remained until present beyond accessibility with traditional assays (Fig. 2). To begin, (i) morphological features of the lung anatomy can be emulated by designing for example ultra-thin and stretchable membranes [20,22,23] to mimic the lung basal membrane or via patterning of the design architecture [11] (e.g. airway tree, generational bifurcations, alveolar cavities, etc.). While such modeling is still far from true lungs [17,22,24], integrating elements of lung anatomy *in vitro* holds important ramifications when investigating aerosol transport and deposition, as discussed further in the next section. In parallel, (ii) microfluidic devices enable the integration of respiratory breathing motion via mechanical model and/or blood-like flows over an endothelium layer on the basal side of the porous membrane. While still few examples of direct microfluidic *in vitro-in vivo* correlations are available, Huh *et al.* [21] revealed in a chip mimicking the lung alveolar-capillary interface that mechanical forces associated with breathing motions are critical in triggering inflammatory responses via cytokine (IL-2) release and in increasing vascular leakage leading to edema; such results corroborated with their *in vivo* experiments in rodents. The authors went on to identify potential new therapeutics which showed promising results both *in vitro* and *in vivo*. Lastly, (iv) *lung-on-chip* platforms of the second generation are now enabling to mimic a major component of the innate cellular microenvironment, i.e. the extra-cellular matrix (ECM) of the lungs. While inserts and PDMS membranes are usually coated with ECM proteins, the possibility to replace the PDMS membrane altogether with a thin, biological and importantly stretchable membrane made of proteins found in the lung ECM represents an important milestone, as recently demonstrated [20]. Taken together these four pillars are now offering a fifth avenue of relevance: the critical opportunity to integrate realistic aerosol transport determinants for *in vitro* inhalation assays.

Strategies to Mimic Inhalation *In Situ*

The past decades have gathered a plethora of supporting evidence, spanning *in vivo* [26–29] (e.g. gamma scintigraphy, MRI, synchrotron radiation CT), *in vitro* [24,30,31] (e.g. extra-thoracic and upper airway casts, microfluidic deep lung models, etc.) and *in silico* [32–35] (e.g. compartment models, trumpet models, computational fluid dynamics, etc.) approaches, that underlines how the interplay between inhalation maneuvers, via respiratory airflows along the airway tree, and aerosol physics (e.g. aerodynamic size, shape, etc.) significantly influences deposition outcomes in the lungs and ensuing efficiencies of inhalation therapy. Aerosol deposition endpoints (e.g. lung region, aerosol concentration, deposition heterogeneity, hot spots [36]) are intimately tied to the physical transport

determinants of an aerosol, in particular through the leading aerosol deposition mechanisms [37–39]: convection (or drag), impaction, sedimentation and Brownian diffusion, as well as interception in the case of non-spherical elongated particulate matter (i.e. fibers [40,41]). Given that these governing mechanisms operate within a highly-intricate network of airways that spans a multitude of length scales (i.e. from centimeters in the extra-thoracic regions to sub-millimeter in the deep acinar regions, see Fig. 1), in conjunction with various gravitational orientations (e.g. apical vs. basal lung lobes) and distinct anatomical confinements (e.g. circular lumen versus alveolar cavities), determining reliably deposition outcomes in a quantitative manner remains challenging.

The prediction of inhaled aerosol deposition is rendered even more arduous in the absence of widely available high-resolution imaging modalities capable of precisely determining aerosol deposition patterns in human lungs; a critical step to corroborate both *in vitro* (and *in silico*) predictions with *in vivo* data. Not only are aerosol deposition data in humans limited (i.e. compared with more widely-available animal models) but existing imaging techniques for *in vivo* aerosol deposition assessment [42] are typically restricted to whole-lung deposition maps of 2D projections (e.g. gamma scintigraphy) partitioned according to coarse regions of interest (e.g. central versus peripheral lung regions). Establishing localized deposition predictions are further exacerbated when considering lungs in a diseased state or under inflamed conditions [43] (e.g. airway obstructions, emphysema, cystic fibrosis, etc.). This results as deposition outcomes are severely compromised compared with healthy airway trees; an outcome clearly visible in whole-lung gamma scintigraphy images. Indeed, much of the overarching paradigms in successful aerosol medicine are bound to airborne particles depositing within the least resistant, more accessible airways or lung lobes. Namely, fluid mechanics of internal (air)flows in a pipe predict that airway narrowing will resist flow passage for a given, fixed breathing effort. Such adverse outcomes accentuate how inhalation therapy is not only heterogeneous in nature but biased in yielding deposition where it is in fact the least needed; an ongoing challenge in devising efficient therapies.

Bearing in mind that the vast majority of the lung surface is contained within the acinar regions, *lung-on-chip* platforms are limited to mimic only a small representative segment of the lungs (Fig. 1), i.e. typically the smaller (e.g. bronchioles) or deep acinar airways. Nevertheless, such systems can replicate more faithfully the airborne delivery route (i.e. from mouth to lumen wall) and thus help improve screening assays in evaluating more precisely those particles that will eventually deposit (Fig. 3). In this context, Benam *et al.*[44] discuss opportunities for microfluidic airway models in COPD research and takes a detailed look in comparing *lung-on-chip* models against both static *in vitro* culture systems and animal models. The authors highlight amongst other the ability to study inhalation exposure to whole smoke under physiological breathing airflow compared with static *in vitro* cultures. Furthermore, *lung-on-chips* offer superior modeling of inhalation toxic-pathology studies and host–pathogen interactions as well as lung anatomy and route of exposure between humans and widely-used rodents. Such new *in vitro* strategies raise opportunities for improved design guidelines when deposition site is of utmost importance (e.g. conductive vs. respiratory regions, see Fig. 1), including for example in the context of topical (e.g. asthma, COPD, infectious diseases) versus systemic delivery [45,46] (e.g. immunization). While the biological endpoints quantified from *lung-on-chips* largely

overlap with or replicate directly those obtained using more traditional *in vitro* models (Fig. 3), incorporating realistic transport outcomes is anticipated to help drug delivery targeting strategies (i.e. designing the carrier size, shape, etc.). Such approaches can help reduce what particles will ultimately be screened or lost during inhalation protocols (including those exhaled), thereby reducing unnecessary secondary effects while increasing the efficiency in delivery payloads to the originally intended airway sites.

Here, we open a short remark in emphasizing that an additional, yet crucial, objective in devising attractive *lung-on-chip* platforms is to reproduce an *in vivo*-like cellular environment, in which lung epithelial cells can maintain their native phenotype; this is in stark contrast to the limitations of working solely with cell lines for example. In such context, both the effect and translocation of inhaled drugs on and across a healthy or diseased air-blood barrier is a key element of the drug discovery process. In particular, a recent study has demonstrated that both type I and type II lung alveolar epithelial cells obtained from patients could be jointly cultured and maintained on chip for several days [22].

Returning to the current paradigms of *in vitro* lung assays, efforts have been made to move beyond instilling liquid suspensions directly onto cell cultures and instead deliver aerosols via direct spraying [47–49]. More recently, *in vitro* designs have included for example the development of the Pharmaceutical Aerosol Deposition Device on Cell Cultures [50] (PADD OCC) for DPIs as well as the air-liquid interface cell exposure (ALICE) setup for nebulized suspensions [51]. Namely, the open cell culture design, characteristic to insert cultures but atypical for microfluidic systems, has been implemented more recently in a number of *lung-on-chip* assays [20,22,23] in an effort to integrate the use of aerosol deposition systems (Fig. 4). While these studies underline the importance of aerosolization at an ALI towards mimicking more truthfully the fate of aerosols depositing on the airway lumen, they come short of replicating the “journey” taken by inhaled aerosols within the lungs (Fig. 1). Such journey is known to result in important aerosol screening “losses” along the airway pathway; a direct result of sedimentation and impaction amongst other. This deposition outcome is emphasized for example in the ICRP deposition curves [52] that are anticipated to reflect to some extent the fate of any inhaled dose. Such aerosol screening phenomenon raises in turn the question of how to appropriately calibrate or adapt deposition results in isolated *lung-on-chip* models, as the entire pathway from mouth to model is absent from the delivery route. Despite such shortcomings, isolated *lung-on-chip* platforms that incorporate physiological airflows and aerosol transport physics (Fig. 2) provide essential steps in uncovering how critical particle size is towards successful localized airway deposition. This was underlined for example in recent microfluidic acinar airway models [24] whereby targeting efficiently aerosols to the deepest regions (i.e. half of all alveoli are located in the last bifurcating generation) remains exceedingly challenging. In particular, we raise the prospect of leveraging *lung-on-chips* for dosimetry applications, as originally motivated with setups such as the PADD OCC, ALICE as well as commercially-available systems such as VITROCELL and Cultex. *In vitro* assays including how effectively an administered dose following an inhalation maneuver (e.g. single metered dose) is deposited with a real inhaler and subsequently absorbed or locally active in the lungs represents appealing new opportunities for exploration in pulmonary drug delivery. In particular, once

the dose of inhaled drugs reaching the lower airways is determined, the ensuing effects of drugs at the air-blood barrier, either for efficacy or safety purposes, can be assessed.

Towards End User Applications

A pertinent advantage of the more established *in vitro* models (i.e. transwell inserts, etc.) lies in the robustness and easiness of their handling due to the relative simplicity of such designs. This includes amongst other the packaging of multiple inserts on plates as well as the static nature of such assays (e.g. lack of complex moving parts). These attributes remain important factors to consider when attempting to translate some of the aforementioned microfluidic *in vitro* platforms for wider use across the scientific community. Although advanced microfluidic-based devices incorporate critical physiological cues (e.g. airflow, strain, etc.) and relevant aerosol exposure characteristics (e.g. particle physics, open microfluidic design, etc.) that ultimately influence biological endpoints under more realistic conditions (e.g. models that resemble more closely drug and molecule dispersal in the human body as well as underlying pathological and toxicological mechanisms), they require undeniably specific training of the end users. These systems are more complex to handle due to their additional characteristics (e.g. breathing movements, flow, etc.). In turn, the design of *lung-on-chip* systems should strive to reach a compromise between the recapitulation of the *in vivo* complexity and the ease of use for the end user, and most importantly the read-out of the specific biological question posed. Ultimately, the designs and robustness of these micro-devices must be such that the end users routinely running the standard biological assays (Fig. 3) are enticed to switch and choose these new available options [53].

The above considerations are important if *lung-on-chips*, and more generally *organ-on-chips*, are considered as realistic options for medium (MTS) or high-throughput screening (HTS) applications; a topic that has drawn attention in recent reviews [54,55]. At present, standard methods for HTS (e.g. well plate readers) enable automated screening endpoints of more than 100,000 drug candidates per day [56]. In contrast, however, *in vitro* tissue models are still far from becoming “high throughput” methods. Nevertheless, *organ-on-chips* technologies are pushing for increasing the experimental throughput as highlighted in various studies [57–61]. In lung research specifically, efforts are still very much in their infancy. Most notably, Stucki *et al.* [23] have recently mimicked several critical features of the alveolar microenvironment including breathing motion at an ALI as well as recapitulating an air-blood barrier, whereby six parallel experiments are simultaneously conducted on a single chip (Fig. 4). As examples, target identification may be carried in simple *in vitro* assays, provided the phenotype of the cells can be maintained, whereas translocation assays of molecules across the alveolar barrier may need cyclic mechanical strain characteristic of breathing motions.

More generally, the path to scale *organ-on-chip* platforms is tightly connected to the added value of the model and the biological question to be answered. In particular, recent discussions on *organ-on-chips* altogether have alluded to the hurdles to overcome for clinical translation of such devices regarding materials, cellular fidelity, multiplexing, sensing, scalability and validation [62]. This is indeed critical, in particular for *lung-on-chips*, when considering their strategic incorporation towards physiologically-based pharmacokinetic

(PBPK)/pharmacodynamic models (PD) in drug development; a topic that has been discussed when considering organ-organ interactions [63]. While beyond our present scope, we raise the prospect and attractiveness of *lung-* and *organ-on-chips* for example in, but not limited to, the validation phase of a selected group of identified drugs, rather than in the initial large-scale screening phase [54,64]. Taking advantage of microfluidic-based *in vitro* models may be attractive in advanced research steps, whereby the value of mimicking more closely the *in situ* physiological environment becomes increasingly significant. Such endeavors are also part of a broader discussion in considering the revision of Good Cell Culture Practice (GCCP) guidance[65].

Outlook

Lung-on-chips have triggered important advances in realizing novel *in vitro* models that strive to mimic more closely the human pulmonary environment. We have argued in this opinion paper that such platforms offer tremendous potential in laying a pipeline for advanced *in vitro* inhalation assays that go far beyond current capabilities with simple transwell inserts of lung cell cultures at an ALI. Yet, their widespread adoption and standard use in the broader research community remain to be established as such novel methods are still not ready for regulatory purposes despite rapid progress; a point recently highlighted in the “Guidance Document on Good *In Vitro* Method Practices (GIVIMP)” [66]. Whether *lung-on-chips* will eventually lead up in delivering new *in vitro* “gold standard” models in pulmonary pharmaceutical research is a point to be monitored over the coming years. The most significant questions are whether *lung-on-chips* can address specific biological questions, and reflect the targeted endpoint as highlighted in the recent review of Hittinger and colleagues [12]. Hence, it is likely that the simpler, more robust designs will prevail while offering the prospect of increased biological complexity with new read-outs unavailable with standard transwell systems. In addressing both physical aerosol transport determinants and cellular barrier functions, *lung-on-chips* have the potential to become a game changer in the respiratory field.

Acknowledgement

This work was supported by the German Israel Foundation (GIF, grant agreement no. I-1348-409.10/2016) and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No 677772). O Guenat thanks the Swiss Science National Foundation (project Nr. 185365) for the generous support.

References

- [1]. Brigden G, Du Cros P, Wong S. Barriers to new drug development in respiratory disease. *Eur Respir J*. 2016; 45 :1197–1207. DOI: 10.1183/13993003.00783-2015
- [2]. Ferkol T, Schraufnagel D. The global burden of respiratory disease. *Ann Am Thorac Soc*. 2014; 11 :404–406. DOI: 10.1513/AnnalsATS.201311-405PS [PubMed: 24673696]
- [3]. Pham T, Rubenfeld GD. Fifty years of research in ards the epidemiology of acute respiratory distress syndrome a 50th birthday review. *Am J Respir Crit Care Med*. 2017; 195 :860–870. DOI: 10.1164/rccm.201609-1773CP [PubMed: 28157386]
- [4]. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. *Nat Biotechnol*. 2014; 32 doi: 10.1038/nbt.2989

- [5]. Humayun M, Chow CW, Young EWK. Microfluidic lung airway-on-a-chip with arrayable suspended gels for studying epithelial and smooth muscle cell interactions. *Lab Chip*. 2018; doi: 10.1039/c7lc01357d
- [6]. Blume C, Reale R, Held M, Millar TM, Collins JE, Davies DE, Morgan H, Swindle EJ. Temporal monitoring of differentiated human airway epithelial cells using microfluidics. *PLoS One*. 2015; doi: 10.1371/journal.pone.0139872
- [7]. Hiemstra PS, Grootaers G, van der Does AM, Krul CAM, Kooter IM. Human lung epithelial cell cultures for analysis of inhaled toxicants: Lessons learned and future directions. *Toxicol Vitro*. 2018; doi: 10.1016/j.tiv.2017.11.005
- [8]. Barrile R, van der Does AM, Park H, Fraser JP, Simic D, Teng F, Conegliano D, Nguyen J, Jain A, Zhou M, Karalis K, et al. Organon-Chip Recapitulates Thrombosis Induced by an anti-CD154 Monoclonal Antibody: Translational Potential of Advanced Microengineered Systems. *Clin Pharmacol Ther*. 2018; 104 :1240–1248. DOI: 10.1002/cpt.1054 [PubMed: 29484632]
- [9]. Mammoto T, Mammoto A, Ingber DE. Mechanobiology and Developmental Control. *Annu Rev Cell Dev Biol*. 2013; 29 :27–61. DOI: 10.1146/annurev-cellbio-101512-122340 [PubMed: 24099083]
- [10]. Waters CM, Roan E, Navajas D. Mechanobiology in lung epithelial cells: Measurements, perturbations, and responses. *Compr Physiol*. 2012; 2 :1–29. DOI: 10.1002/cphy.c100090 [PubMed: 23728969]
- [11]. Artzy-Schnirman A, Zidan H, Elias-Kirma S, Ben-Porat L, Tenenbaum-Katan J, Carius P, Fishler R, Schneider-Daum N, Lehr C, Sznitman J. Capturing the Onset of Bacterial Pulmonary Infection in Acini-On-Chips. *Adv Biosyst*. 2019; doi: 10.1002/adbi.201900026
- [12]. Hittinger M, Schneider-Daum N, Lehr CM. Cell and tissue-based in vitro models for improving the development of oral inhalation drug products. *Eur J Pharm Biopharm*. 2017; 118 :73–78. DOI: 10.1016/j.ejpb.2017.02.019 [PubMed: 28254378]
- [13]. Hittinger M, Juntke J, Kletting S, Schneider-Daum N, de Souza Carvalho C, Lehr CM. Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models. *Adv Drug Deliv Rev*. 2015; 85 :44–56. DOI: 10.1016/j.addr.2014.10.011 [PubMed: 25453270]
- [14]. Lenz AG, Karg E, Brendel E, Hinze-Heyn H, Maier KL, Eickelberg O, Stoeger T, Schmid O. Inflammatory and oxidative stress responses of an alveolar epithelial cell line to airborne zinc oxide nanoparticles at the air-liquid interface: A comparison with conventional, submerged cell-culture conditions. *Biomed Res Int*. 2013; doi: 10.1155/2013/652632
- [15]. Esch EW, Bahinski A, Huh D. Organs-on-chips at the frontiers of drug discovery. *Nat Rev Drug Discov*. 2015; 14 :248–260. DOI: 10.1038/nrd4539 [PubMed: 25792263]
- [16]. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Reconstituting Organ-Level Lung Functions on a Chip. *Science* (80-). 2010; 328 :1662–1668. DOI: 10.1126/science.1188302
- [17]. Tenenbaum-Katan J, Artzy-Schnirman A, Fishler R, Korin N, Sznitman J. Biomimetics of the pulmonary environment in vitro: A microfluidics perspective. *Biomicrofluidics*. 2018; 12 :1–15. DOI: 10.1063/1.5023034
- [18]. Nawroth JC, Barrile R, Conegliano D, van Riet S, Hiemstra PS, Villenave R. Stem cell-based Lung-on-Chips: The best of both worlds? *Adv Drug Deliv Rev*. 2018; doi: 10.1016/j.ADDR.2018.07.005
- [19]. Lee SH, Shim KY, Kim B, Sung JH. Hydrogel-based three-dimensional cell culture for organ-on-a-chip applications. *Biotechnol Prog*. 2017; 3 :580–589. DOI: 10.1002/btpr.2457
- [20]. Zamprogno P, Wüthrich S, Achenbach S, Stucki JD, Hobi N, Schneider-Daum N, Lehr C-M, Huwer H, Geiser T, Schmid RA, Guenat OT. Second-generation lung-on-a-chip array with a stretchable biological membrane. *BioRxiv*. 2019; 608919 doi: 10.1101/608919
- [21]. Huh D, Leslie DC, Matthews BD, Fraser JP, Jurek S, Hamilton GA, Thorneloe KS, McAlexander MA, Ingber DE. A Human Disease Model of Drug Toxicity-Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice. *Sci Transl Med*. 2012; 4 :159ra147 doi: 10.1126/scitranslmed.3004249

- [22]. Stucki AO, Stucki JD, Hall SRR, Felder M, Mermoud Y, Schmid RA, Geiser T, Guenat OT. A lung-on-a-chip array with an integrated bio-inspired respiration mechanism. *Lab Chip*. 2015; 15 :1302–10. DOI: 10.1039/c4lc01252f [PubMed: 25521475]
- [23]. Stucki JD, Hobi N, Galimov A, Stucki AO, Schneider-Daum N, Lehr CM, Huwer H, Frick M, Funke-Chambour M, Geiser T, Guenat OT. Medium throughput breathing human primary cell alveolus-on-chip model. *Sci Rep*. 2018; 8 :14359. doi: 10.1038/s41598-018-32523-x [PubMed: 30254327]
- [24]. Fishler R, Hofemeier P, Etzion Y, Dubowski Y, Sznitman J. Particle dynamics and deposition in true-scale pulmonary acinar models. *Sci Rep*. 2015; 5 :14071. doi: 10.1038/srep14071 [PubMed: 26358580]
- [25]. Guenat OT, Berthiaume F. Incorporating mechanical strain in organs-on-a-chip: Lung and skin. *Biomicrofluidics*. 2018; 12 042207 doi: 10.1063/1.5024895 [PubMed: 29861818]
- [26]. Biddiscombe MF, Meah SN, Underwood SR, Usmani OS. Comparing Lung Regions of Interest in Gamma Scintigraphy for Assessing Inhaled Therapeutic Aerosol Deposition. *J Aerosol Med Pulm Drug Deliv*. 2011; 24 :165–73. DOI: 10.1089/jamp.2010.0845 [PubMed: 21453048]
- [27]. Carvalho TC, Peters JI, Williams RO III. Influence of particle size on regional lung deposition – What evidence is there? *Int J Pharm*. 2011; 406 :1–10. DOI: 10.1016/j.ijpharm.2010.12.040 [PubMed: 21232585]
- [28]. Glover W, Chan HK, Eberl S, Daviskas E, Verschuer J. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. *Int J Pharm*. 2008; 349 :314–22. DOI: 10.1016/j.ijpharm.2007.08.013 [PubMed: 17904774]
- [29]. Stahlhofen W, Rudolf G, James AC. Intercomparison of Experimental Regional Aerosol Deposition Data. *J Aerosol Med*. 2009; 2 doi: 10.1089/jam.1989.2.285
- [30]. Bäckman P, Arora S, Couet W, Forbes B, de Kruijf W, Paudel A. Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs. *Eur J Pharm Sci*. 2018; 113 :41–52. DOI: 10.1016/j.ejps.2017.10.030 [PubMed: 29079338]
- [31]. Heenan AF, Finlay WH, Grgic B, Pollard A, Burnell PKP. An investigation of the relationship between the flow field and regional deposition in realistic extra-thoracic airways. *J Aerosol Sci*. 2004; 35 :1013–1023. DOI: 10.1016/j.jaerosci.2004.03.004
- [32]. Fröhlich E, Mercuri A, Wu S, Salar-Behzadi S. Measurements of deposition, lung surface area and lung fluid for simulation of inhaled compounds. *Front Pharmacol*. 2016; 7 :181. doi: 10.3389/fphar.2016.00181 [PubMed: 27445817]
- [33]. Koullapis P, Kassinos SC, Muela J, Perez-Segarra C, Rigola J, Lehmkuhl O, Cui Y, Sommerfeld M, Elcner J, Jicha M, Saveljic I, et al. Regional aerosol deposition in the human airways: The SimInhale benchmark case and a critical assessment of in silico methods. *Eur J Pharm Sci*. 2018; 113 :77–94. DOI: 10.1016/j.ejps.2017.09.003 [PubMed: 28890203]
- [34]. Vulovi A, Šušteršič T, Cvijić S, Ibrić S, Filipović N. Nouppld in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling. *Eur J Pharm Sci*. 2018; 13 :171–184. DOI: 10.1016/j.ejps.2017.10.022
- [35]. Longest PW, Holbrook LT. In silico models of aerosol delivery to the respiratory tract - development and applications. *Adv Drug Deliv Rev*. 2012; 64 :296–311. DOI: 10.1016/j.addr.2011.05.009 [PubMed: 21640772]
- [36]. Yang L, Feuchtinger A, Möller W, Ding Y, Kutschke D, Möller G, Schittny JC, Burgstaller G, Hofmann W, Stoeger T, Razansky D, et al. Three-Dimensional Quantitative Co-Mapping of Pulmonary Morphology and Nanoparticle Distribution with Cellular Resolution in Nondissected Murine Lungs. *ACS Nano*. 2019; 13 :1029–1041. DOI: 10.1021/acsnano.8b07524 [PubMed: 30566327]
- [37]. Darquenne C. Aerosol Deposition in Health and Disease. *J Aerosol Med Pulm Drug Deliv*. 2012; 25 :140–147. DOI: 10.1089/jamp.2011.0916 [PubMed: 22686623]
- [38]. Sznitman J. Respiratory microflows in the pulmonary acinus. *J Biomech*. 2013; 46 :284–298. DOI: 10.1016/j.jbiomech.2012.10.028 [PubMed: 23178038]
- [39]. Hinds, William C. *Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles*. Wiley; 1999.

- [40]. Belka M, Lizal F, Jedelsky J, Elcner J, Hopke PK, Jicha M. Deposition of glass fibers in a physically realistic replica of the human respiratory tract. *J Aerosol Sci.* 2018; 117 :149–163. DOI: 10.1016/j.jaerosci.2017.11.006
- [41]. Dastan A, Abouali O, Ahmadi G. CFD simulation of total and regional fiber deposition in human nasal cavities. *J Aerosol Sci.* 2014; 69 :132–149. DOI: 10.1016/j.jaerosci.2013.12.008
- [42]. Conway J. Lung imaging - Two dimensional gamma scintigraphy, SPECT, CT and PET. *Adv Drug Deliv Rev.* 2012; 64 :357–68. DOI: 10.1016/j.addr.2012.01.013 [PubMed: 22310158]
- [43]. Bennett WD, Xie M, Zeman K, Hurd H, Donaldson S. Heterogeneity of Particle Deposition by Pixel Analysis of 2D Gamma Scintigraphy Images. *J Aerosol Med Pulm Drug Deliv.* 2014; 28 :211–8. DOI: 10.1089/jamp.2013.1095 [PubMed: 25393109]
- [44]. Benam KH, Königshoff M, Eickelberg O. Breaking the in vitro barrier in respiratory medicine: Engineered microphysiological systems for chronic obstructive pulmonary disease and beyond. *Am J Respir Crit Care Med.* 2018; doi: 10.1164/rccm.201709-1795PP
- [45]. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination: an update. *Transl Respir Med.* 2014; 2 :1–12. DOI: 10.1186/2213-0802-2-3 [PubMed: 25984445]
- [46]. Laube BL. Aerosolized Medications for Gene and Peptide Therapy. *Respir Care.* 2015; 60 :806–21. DOI: 10.4187/respcare.03554 [PubMed: 26070576]
- [47]. Blank F, Rothen-Rutishauser BM, Schurch S, Gehr P. An optimized in vitro model of the respiratory tract wall to study particle cell interactions. *J Aerosol Med Off J Int Soc Aerosols Med.* 2006; 19 :392–405. DOI: 10.1089/jam.2006.19.392
- [48]. Lenz AG, Stoeger T, Cei D, Schmidmeier M, Semren N, Burgstaller G, Lentner B, Eickelberg O, Meiners S, Schmid O. Efficient bioactive delivery of aerosolized drugs to human pulmonary epithelial cells cultured in air-liquid interface conditions. *Am J Respir Cell Mol Biol.* 2014; 51 :526–35. DOI: 10.1165/rcmb.2013-0479OC [PubMed: 24773184]
- [49]. Röhm M, Carle S, Maigler F, Flamm J, Kramer V, Mavoungou C, Schmid O, Schindowski K. A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery. *Int J Pharm.* 2017; 532 :537–546. DOI: 10.1016/j.ijpharm.2017.09.027 [PubMed: 28917988]
- [50]. Hein S, Bur M, Kolb T, Muellinger B, Schaefer UF, Lehr CM. The Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDCCC) in vitro system: Design and experimental protocol. *ATLA Altern to Lab Anim.* 2010; 38 :285–95.
- [51]. Herzog F, Loza K, Balog S, Clift MJD, Epple M, Gehr P, Petri-Fink A, Rothen-Rutishauser B. Mimicking exposures to acute and lifetime concentrations of inhaled silver nanoparticles by two different in vitro approaches. *Beilstein J Nanotechnol.* 2014; 5 :1357–70. DOI: 10.3762/bjnano.5.149 [PubMed: 25247119]
- [52]. ICRP, Human Respiratory Tract Model for Radiological Protection. *ICRP Publ 66 Ann ICRP.* 1994; 24 :1–3.
- [53]. Junaid A, Mashaghi A, Hankemeier T, Vulto P. An end-user perspective on Organ-on-a-Chip: Assays and usability aspects. *Curr Opin Biomed Eng.* 2017; 1 :15–22. DOI: 10.1016/j.cobme.2017.02.002
- [54]. Probst C, Schneider S, Loskill P. High-throughput organ-on-a-chip systems: Current status and remaining challenges. *Curr Opin Biomed Eng.* 2018; 6 :33–41. DOI: 10.1016/j.cobme.2018.02.004
- [55]. Uhl C, Shi W, Liu Y. Organ-on-Chip Devices Toward Applications in Drug Development and Screening. *J Med Device.* 2018; 12 040801 doi: 10.1115/1.4040272
- [56]. Szymański P, Markowicz M, Mikiciuk-Olasik E. Adaptation of high-throughput screening in drug discovery-toxicological screening tests. *Int J Mol Sci.* 2012; 13 :427–452. DOI: 10.3390/ijms13010427 [PubMed: 22312262]
- [57]. Domansky K, Inman W, Serdy J, Dash A, Lim MHM, Griffith LG. Perfused multiwell plate for 3D liver tissue engineering. *Lab Chip.* 2010; 10 :51–8. DOI: 10.1039/b913221j [PubMed: 20024050]
- [58]. Phan DTT, Wang X, Craver BM, Sobrino A, Zhao D, Chen JC, Lee LYN, George SC, Lee AP, Hughes CCW. A vascularized and perfused organ-on-a-chip platform for large-scale drug

- screening applications. *Lab Chip*. 2017; 17 :511–520. DOI: 10.1039/c6lc01422d [PubMed: 28092382]
- [59]. Wevers NR, Van Vught R, Wilschut KJ, Nicolas A, Chiang C, Lanz HL, Trietsch SJ, Joore J, Vulto P. High-throughput compound evaluation on 3D networks of neurons and glia in a microfluidic platform. *Sci Rep*. 2016; 6 38856 doi: 10.1038/srep38856 [PubMed: 27934939]
- [60]. Gumuscu B, Albers HJ, Van Den Berg A, Eijkel JCT, Van Der Meer AD. Compartmentalized 3D Tissue Culture Arrays under Controlled Microfluidic Delivery. *Sci Rep*. 2017; 7 :3381. doi: 10.1038/s41598-017-01944-5 [PubMed: 28611357]
- [61]. Lecault V, Vaninsberghe M, Sekulovic S, Knapp DJHF, Wohrer S, Bowden W, Viel F, McLaughlin T, Jarandehi A, Miller M, Falconnet D, et al. High-throughput analysis of single hematopoietic stem cell proliferation in microfluidic cell culture arrays. *Nat Methods*. 2011; 8 :581–586. DOI: 10.1038/nmeth.1614 [PubMed: 21602799]
- [62]. Zhang B, Korolj A, Lai BFL, Radisic M. Advances in organ-on-a-chip engineering. *Nat Rev Mater*. 2018; doi: 10.1038/s41578-018-0034-7
- [63]. A HE, Shuler ML. Human-on-a-chip design strategies and principles for physiologically based pharmacokinetics/pharmacodynamics modeling. *Integr Biol*. 2015; doi: 10.1039/C4IB00292J
- [64]. Zhang B, Radisic M. Organ-on-a-chip devices advance to market. *Lab Chip*. 2017; 17 :2395–2420. DOI: 10.1039/C6LC01554A [PubMed: 28617487]
- [65]. Pamies D, Bal-Price A, Simeonov A, Tagle D, Allen D, Gerhold D, Yin D, Pistollato F, Inutsuka T, Sullivan K, Stacey G, et al. Good cell culture practice for stem cells & stem-cell-derived models. *ALTEX*. 2017; doi: 10.14573/altex.1607121
- [66]. OECD. Guidance Document on Good In Vitro Method Practices (GIVIMP). OECD Guid Test Chem. 2018

Figure 1.

The lungs encompass a complex multiscale organ with a cascade of airways covering a wide range of length scales (i.e. anatomy), from several centimeters to sub-millimeters (i.e. ~100 μm). In parallel, the organ covers a diverse cellular make-up that may be broadly categorized according to three main regions: extra-thoracic, conductive and respiratory. Translating pulmonary organ functions to relevant *in vitro* platforms comprising truthful physiological and biological functionalities requires limiting a model (e.g. microfluidics) to an isolated region of interest as a result of the multiscale challenge.

Figure 2.

Lung-on-chip platforms mimic the smallest functional biological units of the lungs, such as the lung alveolar barrier and/or the acinar airspace. They further enable to critically account for physical and physiological cues that go beyond traditional *in vitro* models at an air-liquid interface (ALI). The principal advantages include (i) mimicking elements of airway morphology (i.e. anatomy), (ii) incorporating the influence of mechanical strain due to breathing (i.e. stretching cells), (iii) implementing flow physiology resulting from representative respiratory airflows at the ALI as well as blood flows (on the basal side

of the porous membrane) and (iv) mimic the basal membrane that supports the air-blood barrier. Importantly, *lung-on-chips* can deliver realistic aerosol transport assays that mimic the physics of inhaled particles (i.e. droplets or particulate matter), from airborne flight to wall deposition.

Figure 3.

Schematic of the *in vitro* pipeline for inhalation assays with advanced microfluidic platforms. Input parameter screens include exploring the carrier design (e.g. particle size, shape, etc.), the inhalation protocol (e.g. flow and breathing rate) as well as the drug or compound (e.g. composition and formulation). In analogy to traditional *in vitro* models (e.g. transwell inserts), output parameters of interest feature well-established biological endpoints (e.g. cytokine secretion, viability, gene expression, etc.) and barrier properties (e.g. permeability, TEER, etc.) as well as a new opportunity to characterize directly the outcomes of aerosol deposition (e.g. location and concentration).

Figure 4.

(A) Prototype of a *lung-on-chip* design featuring six wells, following the work of Stucki *et al.* [23], mimicking the lung alveolar barrier whereby cells are cultured directly at an air-liquid interface (ALI). (B) and (C) The *lung-on-chip* design is integrated with an *in vitro* inhalation system for liquid aerosol deposition. The setup allows for aerosol exposure and breathing concurrently, under controlled temperature conditions. Additionally, such setup can be equipped with a Quartz Crystal Microbalance (QCM) for online particle counting.